|Articles|September 14, 2021
- Pharmaceutical Executive-09-01-2021
- Volume 41
- Issue 9
Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
When Innovation Outpaces HTA, Access Struggles to Keep Upalmost 5 years ago
Doubling Down On Innovation, Recoveryalmost 5 years ago
Developing a Product Launch Strategy for an Orphan Drugalmost 5 years ago
Investing for Success: Finding the Right Launch Balancealmost 5 years ago
Rethinking Obesity: Wegovyalmost 5 years ago
Fear Factor: Palforziaalmost 5 years ago
Formidable Option: Orgovyxalmost 5 years ago
No Small Feat: Nurtec ODTalmost 5 years ago
‘Rare’ Reinforcement: Evrysdialmost 5 years ago
Serial Problem SolverAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351
2
President Trump Set to Nominate Heidi Overton as FDA Commissioner
3
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
4
Pharmaceutical Executive Daily: Unpacking IRA-Driven Formulary Pressure
5